Last reviewed · How we verify

D-serine solution — Competitive Intelligence Brief

D-serine solution (D-serine solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor co-agonist. Area: Neurology/Psychiatry.

phase 3 NMDA receptor co-agonist NMDA receptor (glycine site) Neurology/Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

D-serine solution (D-serine solution) — University of Minnesota. D-serine acts as a co-agonist at the N-methyl-D-aspartate (NMDA) receptor by binding to the glycine site, enhancing glutamatergic neurotransmission.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
D-serine solution TARGET D-serine solution University of Minnesota phase 3 NMDA receptor co-agonist NMDA receptor (glycine site)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor co-agonist class)

  1. University of Minnesota · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). D-serine solution — Competitive Intelligence Brief. https://druglandscape.com/ci/d-serine-solution. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: